An apabetalone abstract was presented at the American Thoracic Society 2018 International Conference May 18-23, 2018 in San Diego. The research focused on the beneficial effects of apabetalone on pulmonary arterial hypertension (PAH) endpoints in both human pulmonary artery smooth muscle cells as well as an in vivo rat model of PAH. The work was done in collaboration with the Pulmonary Hypertension Research group, CRIUCPQ, Quebec City, Canada and presented by Eve Tremblay from that institution. Here's a link to the abstract.

Apabetalone (RVX-208) Alone and in Combination with Standard of Care Improves Experimental PAH in Sugen-Hypoxia Rat Model

They observed beneficial effects in both the human cell model and the in vivo rat model. The last sentence is exciting:

"Given that Apabetalone is in a phase 3 trial of MACE outcomes in cardiovascular disease, our study supports the development of an early proof of concept clinical trial in PAH patients"

Thanks to rndtbl over on Investor Village for posting. Glad others like rndtbl are good internet hunters of Resverlogix related presentations. I missed this one. Why isn't Resverlogix promoting this stuff???

BearDownAZ